Showing results (51-60 of 92) with videos related to
Sort By:
Pageof 10
Frontiers in Medicine|February 20, 2026
Novel diagnostic approaches and therapeutic management of mucormycosis: insights from a retrospective monocentric cohort studyOthman Lemhamdi, Evelyne Willems, Frédéric Baron, et al.Genes, Chromosomes & Cancer|July 26, 2016
Genomic studies of multiple myeloma reveal an association between X chromosome alterations and genomic profile complexityTiberio Sticca, Jean-Hubert Caberg, Stephane Wenric, et al.Frontiers in Immunology|December 29, 2025
Development of a humanized mouse model of graft-versus-host disease to assess human regulatory T cell functionCharline Beguin, Oswin Kwan, Grégory Ehx, et al.British Journal of Haematology|April 2, 2020
The anti-mitotic agents PTC-028 and PTC596 display potent activity in pre-clinical models of multiple myeloma but challenge the role of BMI-1 as an essential tumour geneArnold Bolomsky, Joséphine Muller, Kathrin Stangelberger, et al.Journal of Hematology & Oncology|July 6, 2016
Azacytidine mitigates experimental sclerodermic chronic graft-versus-host diseaseGilles Fransolet, Grégory Ehx, Joan Somja, et al.Cancers|March 1, 2019
Loss of Stromal Galectin-1 Enhances Multiple Myeloma Development: Emphasis on a Role in OsteoclastsJoséphine Muller, Elodie Duray, Margaux Lejeune, et al.Oncotarget|April 21, 2016
SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myelomaRoy Heusschen, Joséphine Muller, Marilène Binsfeld, et al.Immunity|May 22, 2024
Single-cell proteomics and transcriptomics capture eosinophil development and identify the role of IL-5 in their lineage transit amplificationJoseph Jorssen, Glenn Van Hulst, Kiréna Mollers, et al.Journal of Clinical Epidemiology|March 23, 2021
The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3LEva M Gamper, Francesco Cottone, Kathrin Sommer, et al.Haematologica|May 12, 2018
Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity in multiple myeloma bone diseaseJoséphine Muller, Arnold Bolomsky, Sophie Dubois, et al.Pageof 10